Journal of Clinical Pharmacy and Therapeutics · 2013 · 29 citations · 4 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyCritical Care PharmacotherapyAntifungal PharmacologyAntifungal PharmacotherapyCardiopulmonary ResuscitationCardiovascular Drug SafetyCardiovascular InstabilityPharmacodynamics In Critical IllnessAcute Cardiac ToxicityAdult Cardiopulmonary ResuscitationCandida Albicans InfectionCandida Infection ManagementCandida TherapyFungal Infections In Intensive Care UnitsNeutropenic InfectionsPharmacodynamics Of Antifungal Drugs
WHAT IS KNOWN AND OBJECTIVE: Anidulafugin is an echinocandin used for the treatment of candida infections in non-neutropenic adults. Echinocandins show few drug-drug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration. CASE SUMMARY: A 41-year-old man ICU patient received anidulafungin for a suspected Candida glabrata infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability. WHAT IS NEW AND CONCLUSION: To the authors' knowledge, this is the first report of a life-threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.
4
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Andrew J. Ullmann, Oliver A. Cornely, J.P. DonneNy et al. · Clinical Microbiology and Infection · 2012 · 149 citations · Full text